Du har inte javascript påslaget. Det innebär att många funktioner inte fungerar. För mer information om Vinnova, ta kontakt med oss.

Development of Foxy-5 as a first in class anti-metastatic cancer drug

Koordinator Wntresearch AB
Bidrag från Vinnova 5 000 000 kronor
Projektets löptid mars 2012 - februari 2015
Status Avslutat

Syfte och mål

The goal of the project was to bring Foxy-5 into humans as an anti-metastatic anti-cancer compound. It was clear from the original project description, that with the funding and the time frame of the Eurostars grant, we could at best reach initiation of a clinical phase 2 study. Due to the results obtained during the preclinical tox testing and the clinical phase 1 study, we decided to introduce a clinical phase 1b study in order to obtain a better basis for selecting the dose of Foxy-5 to be used in the phase 2 study.

Resultat och förväntade effekter

We have finalized clinical phase 1 and are ready to initiate clinical phase 1b. We expect that we during 2017 can initiate a pivotal randomized clinical phase 2 study which if successful will allow us to apply the Health Authorities for a conditional approval for Foxy-5 use in cancer patients. Moreover, with such data we will be in a very good position to discuss partnerships with big Pharma.

Upplägg och genomförande

The clinical results obtained in WP3 were exceptionally positive in that no dose-limiting toxicity was seen with the planned maximum dosing in humans (patients). Thus, WP7 was redesigned to investigate higher dosages and hence also possibly identifying a dose-limiting toxicity at a higher level. In addition, as originally planned for WP7, the analysis of potential biological surrogate markers would possibly give initial signals of efficacy.

Texten på den här sidan har projektgruppen själv formulerat. Innehållet är inte granskat av våra redaktörer.

Senast uppdaterad 8 maj 2017

Diarienummer 2012-00116

Statistik för sidan